Physician profile
Michael J Bateman
NPI 1215900279
$3,826.11
in general payments reported to CMS, 2019-2025
37 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,893 · 2020: $485 · 2021: $60.62 · 2023: $141 · 2024: $246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $387.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $386.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mentor Worldwide LLC | $557.99 | 2019-2024 | Mentor Memorygel Resterilizable Gel Sizer |
| Amgen INC. | $329.09 | 2019-2020 | |
| Lilly USA, LLC | $304.11 | 2019-2020 | |
| Novo Nordisk INC | $304.05 | 2019-2020 | |
| Pfizer INC. | $246.07 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $243.47 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $227.92 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $197.96 | 2019 | |
| Janssen Pharmaceuticals, INC | $190.77 | 2019 | |
| Merck Sharp & Dohme LLC | $182.60 | 2019-2020 | |
| Tepha INC | $171.08 | 2019 | |
| Daiichi Sankyo INC. | $89.47 | 2019-2020 | |
| Radius Health, INC. | $83.21 | 2019-2020 | |
| Bausch Health US, LLC | $64.77 | 2019 | |
| Sanofi-Aventis U.S. LLC | $59.83 | 2019 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $54.92 | 2019-2020 | |
| Horizon Therapeutics Plc | $41.93 | 2019 | |
| Novartis Pharmaceuticals Corporation | $38.07 | 2019 | |
| Abbvie INC. | $35.44 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.88 | 2020 | |
| Circassia INC. | $33.12 | 2019-2020 | |
| Allergan, INC. | $31.97 | 2020 | |
| Alfasigma USA, INC. | $28.26 | 2020 | |
| Arbor Pharmaceuticals, INC. | $26.62 | 2019 | |
| Nevro Corp. | $25.19 | 2019 | |
| Therapeuticsmd, INC. | $23.61 | 2019 | |
| Sunovion Pharmaceuticals INC. | $22.22 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $20.34 | 2019 | |
| Genentech USA, INC. | $20.31 | 2020 | |
| Glaxosmithkline, LLC. | $19.16 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $19.02 | 2024 | |
| Ironwood Pharmaceuticals, INC | $18.35 | 2020 | |
| Seqirus USA INC | $17.63 | 2020 | |
| Amarin Pharma, INC. | $17.28 | 2020 | |
| Antares Pharma, INC. | $16.57 | 2019 | |
| Becton, Dickinson and Company | $16.22 | 2019 | |
| Neuronetics, INC. | $13.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Bateman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.